[go: up one dir, main page]

AR077081A1 - A 4-METHYLBENBENOSULFONATE SALT AND A PROCESS TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SALT - Google Patents

A 4-METHYLBENBENOSULFONATE SALT AND A PROCESS TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SALT

Info

Publication number
AR077081A1
AR077081A1 ARP100102083A ARP100102083A AR077081A1 AR 077081 A1 AR077081 A1 AR 077081A1 AR P100102083 A ARP100102083 A AR P100102083A AR P100102083 A ARP100102083 A AR P100102083A AR 077081 A1 AR077081 A1 AR 077081A1
Authority
AR
Argentina
Prior art keywords
salt
pharmaceutical composition
methylbenbenosulfonate
prepare
methylbenzenesulfonate
Prior art date
Application number
ARP100102083A
Other languages
Spanish (es)
Inventor
Antonio Mete
Karolina Nilsson
Stefan Nystrom
Eva Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR077081A1 publication Critical patent/AR077081A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

4-metilbencenosulfonato de un antagonista muscarínico y su uso en terapia, y un proceso para preparar una composicion farmacéutica que comprende la sal y su uso en terapia. Reivindicacion 1: Una sal caracterizada porque es el 4-metilbencenosulfonato de (R)-1-(4-fluorofenetil)-3-((S)-2-fenil-2-(piperidin-1-il)propanoiloxi)-1-azoniabiciclo[2.2.2]octano.4-methylbenzenesulfonate of a muscarinic antagonist and its use in therapy, and a process for preparing a pharmaceutical composition comprising salt and its use in therapy. Claim 1: A salt characterized in that it is the 4-methylbenzenesulfonate of (R) -1- (4-fluorofenetyl) -3 - ((S) -2-phenyl-2- (piperidin-1-yl) propanoyloxy) -1- azoniabicyclo [2.2.2] octane.

ARP100102083A 2009-06-12 2010-06-11 A 4-METHYLBENBENOSULFONATE SALT AND A PROCESS TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SALT AR077081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18645909P 2009-06-12 2009-06-12
US24938309P 2009-10-07 2009-10-07
US28686509P 2009-12-16 2009-12-16

Publications (1)

Publication Number Publication Date
AR077081A1 true AR077081A1 (en) 2011-07-27

Family

ID=43309104

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102083A AR077081A1 (en) 2009-06-12 2010-06-11 A 4-METHYLBENBENOSULFONATE SALT AND A PROCESS TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SALT

Country Status (4)

Country Link
AR (1) AR077081A1 (en)
TW (1) TW201100414A (en)
UY (1) UY32703A (en)
WO (1) WO2010144043A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BRPI0721039A2 (en) * 2006-12-19 2014-07-29 Astrazeneca Ab "QUINUCLIDINOL DERIVATIVES AS ANTAGONISTS OF MUSCARINE RECEPTORS".
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
RU2011101664A (en) * 2008-06-20 2012-07-27 Астразенека Аб (Se) Pharmaceutical composition containing 4-hydroxy-2-oxo-2, 3-dihydro-1, 3-benzothiazole-7-compound, for modulating the activity of beta-2-adrenergic receptors

Also Published As

Publication number Publication date
WO2010144043A1 (en) 2010-12-16
UY32703A (en) 2011-01-31
TW201100414A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
PE20140960A1 (en) FORMULATIONS INVOLVING A DPP4 INHIBITOR
CL2013001677A1 (en) Compounds derived from azabicyclo [3.2.1] octane; x fernesoid receptor agonist (fxr); process to prepare the compounds; intermediate compound; pharmaceutical composition and pharmaceutical combination that comprise a compound; and use of the compounds in the preparation of medicaments for the treatment of dyslipidemia.
CU20150020A7 (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
CL2008002271A1 (en) (2s, 3r) -n- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide or its pharmaceutical salt; Preparation process; intermediary compounds; pharmaceutical composition comprising said compound; and use of the compound to treat a disorder of the central nervous system such as Alzheimer's, senile dementia, parkinson's.
CL2012000702A1 (en) Use of an alpha-7 nicotinic acetylcholine receptor agonist for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.
ECSP077999A (en) FORMULATIONS OF A MODIFIED LIBERATION BUPROPION SALT
CL2007001318A1 (en) Use of flibanserin, optionally as a free base, hydrate salt or solvate thereof, to prepare a useful medication in the treatment of sexual desire disorders in women.
CL2007001435A1 (en) Phenylalanine derivative compounds; preparation process; pharmaceutical composition comprising said compound; and use of the compound as integrin inhibitors for the treatment of cancer.
CR20140182A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS
AR077199A1 (en) PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE FOR EMERGENCY ANTI-CONCEPTION
CL2012003656A1 (en) Use of a composition comprising a replacement enzyme for the lysosomal enzyme at a concentration greater than 5 mg / ml to treat somatic symptoms of the underlying enzyme deficiency.
ECSP12012213A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC AGONISTS? 2 AND AS M3 MUSCARINIC ANTAGONISTS
UY30440A1 (en) NEW COMPOUNDS
ECSP14013340A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC AGONISTS? 2 AND AS M3 MUSCARINIC ANTAGONISTS
CL2007001648A1 (en) Leptomycin derived compound; conjugate comprising cell binding agent bound to one or more of said derivatives; pharmaceutical compositions comprising said derivative or conjugate; useful in the treatment of cancer; process of preparing a compound or a conjugate of a leptomycin derivative.
AR063188A1 (en) INTERMEDIARY COMPOUNDS FOR THE PREPARATION OF TRANS -5-CHLORO-2-NETIL-2,3,3A, 12B- TETRAHIDRO-1H-DIBENZ (2,3: 6,7) - OXEPINA (4,5C) PIRROL
CL2008001671A1 (en) Dgat1 inhibitor piperidine / piperazine derivative compounds, pharmaceutical composition comprising them; and its use in the treatment of metabolic diseases especially diabetes.
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
AR066206A1 (en) PROCESS FOR SYNTHESIS OF SOLIFENACINE
AR066701A1 (en) 3- (IMIDAZOLIL) - PIRAZOLO {3,4-B] PIRIDINES, PHARMACEUTICAL COMPOSITION, PROCESS AND USE IN THERAPY
BRPI0907992A2 (en) pharmaceutically acceptable compound or salt thereof, use thereof, pharmaceutical composition, method of therapy in a warm-blooded animal, and process for preparing a compound
CY1115077T1 (en) CRYSTAL FORMS OF THE 8-AZADICYLIC [3.2.1] OCTANE UNION
CL2008002545A1 (en) Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
CL2009001137A1 (en) Compounds derived from cycloheptanecarbonyloxy-1-azonia-bicyclo [2.2.2] -octane, modulators of muscarinic receptors; pharmaceutical compositions; process of preparation of said composition; and use in the treatment of chronic obstructive pulmonary disease.
UY31758A (en) ORVEPITANT MALEATE ANHYDRA CRYSTAL FORM

Legal Events

Date Code Title Description
FB Suspension of granting procedure